サンプル依頼リスト カート
  • English
  • Korean
表紙：骨がん治療の世界市場-2023年～2030年
市場調査レポート
商品コード
1347971

骨がん治療の世界市場-2023年～2030年

Global Bone Cancer Treatment Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
骨がん治療の世界市場-2023年～2030年
出版日: 2023年09月11日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

骨がんは、骨内の細胞の制御不能な増殖を特徴とします。異なるタイプの骨組織が異なるタイプの原発性骨がんを発生させます。骨肉腫は骨を形成する細胞から発生し、ユーイング肉腫は骨内の未熟な神経組織から発生します。骨がんは全がんの1％未満を占めるまれながんで、骨盤や腕や脚の長い骨によく発生します。

世界の骨がん市場は、骨がんに対するCAR T細胞療法などの免疫療法技術の採用により、近年著しい成長を遂げています。例えば、B7-H3を標的としたCAR-T細胞は、in vivoでユーイング肉腫の異種移植片を根絶することができ、生存率の大幅な向上につながります。

さらに、製品承認の増加、骨がん治療への投資、研究開発などの重要な成長促進要因が、将来の市場成長をもたらします。イーライリリー・アンド・カンパニー、ファイザー、マイクロバイオファーム・ジャパン、スターリング・バイオテック、Teva Pharmaceuticals Industries Ltd.などの主要企業が市場で活発に活動しています。

市場力学

骨がんの研究開発の増加

世界の骨がん治療市場は、最近のさまざまな研究開発により大きな成長を遂げています。骨がんは通常、病歴や臨床所見、画像所見に基づいて診断されます。また、主要な骨がんの治療における先進的な研究開発は、市場成長の加速に役立っています。

例えば、2023年3月、イースト・アングリア大学の研究者は、すべての主要なタイプの原発性骨がんに効く新薬を開発しました。「CADD522」と呼ばれるこの新薬は、がんの拡散を促進する遺伝子をブロックし、手術や化学療法を必要とせずに生存率を50％向上させます。

さらに、米国国立衛生研究所（National Institue of Health）によると、2022年1月に発表された「進行軟骨肉腫の治療標的と新たな治療法」と題する論文によると、最近の研究で、IDH1/2、COL2A1、PD-L1など軟骨肉腫のいくつかのバイオマーカーと治療標的が示されました。さらに、進行軟骨肉腫患者を対象とした臨床研究において、いくつかの分子標的薬や免疫療法が良好な抗腫瘍効果を示しています。

骨がん治療への投資の増加

骨がんは、骨に腫瘍や異型の組織塊が形成されることで発生し、腫瘍は悪性であることも良性であることもあります。主要企業からの大規模な投資は市場成長の原動力となり、国家機関や企業からのこうした効果的な資金は、研究発見を骨がんの新たな治療法に変えるのに役立っています。

例えば、2023年8月、Zetagen Therapeuticsは、転移性骨がんと軟部組織腫瘍の治療のためのZetaMetとZetaMASTの進歩のために、979万米ドルのシリーズB資金調達を確保しました。ZetaMetは、がんを停止させ、痛みを抑制し、骨を再生するように設計された最初の分子経路です。

さらに、修正登録届出書2021によると、インヒブレックス（INBX）は普通株式の売却により1億200万米ドルを調達することを申請しました。同社は現在、軟骨肉腫や中皮腫などの希少がんやその他のがんに対するさまざまな潜在的治療法を開発しています。したがって、上記の要因により、市場は予測期間中に拡大すると予想されます。

化学療法に伴う副作用が世界の骨がん治療市場を阻害すると予想される

化学療法は、腫瘍細胞を破壊したり成長を遅らせたりするために薬剤を使用する、広く使用されているがん治療法です。しかし、化学療法は体内の健康な細胞にも影響を及ぼし、様々な副作用を引き起こします。

例えば、白血病財団は、化学療法は毛髪細胞や口、腸、骨髄の組織を構成する細胞など、急速に成長する正常細胞に害を及ぼす可能性があると述べています。さらに、化学療法は、十分な量の血液細胞を生成する骨髄の能力に影響を及ぼし、治療後1週間以内に血液数が減少する可能性があります。したがって、上記の要因のために、市場は予測期間中に低迷すると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 骨がんの研究開発の増加
      • 骨がん治療への投資の増加
    • 抑制要因
      • 化学療法に伴う副作用
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • アンメットニーズ
  • 規制分析
  • DMIの見解

第6章 COVID-19分析

第7章 タイプ別

  • 原発性骨がん
    • 骨肉腫
    • 軟骨肉腫
    • ユーイング肉腫
    • 脊索腫
  • 続発性骨がん
    • 骨転移

第8章 治療法別

  • 手術療法
  • 化学療法
    • ドキソルビシン
    • シスプラチン
    • エトポシド
    • ビンクリスチン
  • 放射線療法
    • 陽子線放射線療法
    • 定位放射線手術
    • 強度変調放射線療法
  • 標的療法
  • 免疫療法
  • その他

第9章 エンドユーザー別

  • 病院
  • 腫瘍センター
  • 外来手術センター
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 製品ベンチマーク
  • 企業シェア分析
  • 主な動向と戦略

第12章 企業プロファイル

  • Pfizer Inc.
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • MicroBiopharm Japan Co. Ltd.
  • Sterling Biotech Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • Cipla Ltd.
  • Aspen API Inc.
  • Eli Lilly and Company
  • Gatewell Oncology Pvt. Ltd.
  • Recordati Rare Diseases Inc.
  • Novartis AG

第13章 付録

目次
Product Code: PH2058

Overview

Bone cancer is characterized by the uncontrolled growth of cells in the bone. Different types of bone tissue give rise to different types of primary bone cancer. Osteosarcoma develops from cells that form the bone, and Ewing sarcoma develops from immature nerve tissue within the bone. Bone cancer is rare which makes up less than 1 percent of all cancers and commonly affects the pelvis or the long bones in the arms and legs.

The global bone cancer market has witnessed significant growth in recent years due to the adoption of immunotherapy techniques such as CAR T-cell therapy for bone cancers. For instance, B7-H3-targeted CAR-T cells can eradicate ewing sarcoma xenografts in vivo which leads to significant survival advantages.

Furthermore, significant growth drivers such as increasing product approvals, investments for bone cancer treatment, and research and developments give rise to future market growth. Significant key players like Eli Lilly and Company, Pfizer Inc., MicroBiopharm Japan Co. Ltd., Sterling Biotech Ltd., Teva Pharmaceuticals Industries Ltd., and others are actively operating in the market.

Market Dynamics

Increasing research and developments for bone cancers

The global bone cancer treatment market has witnessed significant growth due to various recent research and developments. Bone cancer is usually diagnosed on the basis of medical history and clinical and imaging findings. Also, advanced research and developments in treating major bone cancers help to accelerate market growth.

For instance, in March 2023, researchers at the University of East Anglia developed a new drug that works against all of the main types of primary bone cancer. This new drug called 'CADD522' blocks a gene associated with driving cancer's spread and increases survival rates by 50 percent without the need for surgery or chemotherapy.

Additionally, according to the National Institue of Health, an article entitled Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma published in January 2022 states that recent studies showed several biomarkers and therapeutic targets for chondrosarcoma including IDH1/2, COL2A1, and PD-L1. In addition, several molecule-targeting agents and immunotherapy have shown favorable antitumor activities in clinical studies of patients with advanced chondrosarcoma.

Increasing investments for bone cancer treatment

Bone cancer occurs when a tumor, or atypical mass of tissue forms in a bone, and the tumor can be malignant or benign in nature. The major investments from key companies help to drive market growth and these effective funds from national organizations and companies help to transform research discoveries into new treatments for bone cancers.

For instance, in August 2023, Zetagen Therapeutics secured a 9.79 Million USD Series B Funding raise for the advancement of ZetaMet and ZetaMAST for the treatment of metastatic bone cancers and soft tissue tumors. ZetaMet is the first molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone.

Additionally, according to an amended registration statement 2021, Inhibrx (INBX) has filed to raise $102 million from the sale of its common stock. The company is currently developing a range of potential treatments for rare types of cancer such as chondrosarcoma and mesothelioma, as well as other forms of cancer. Thus, owing to the above factors the market is expected to boost over the forecast period.

Aftereffects associated with chemotherapy are expected to hamper global bone cancer treatment market

Chemotherapy is a widely used cancer treatment that involves the use of drugs to destroy or slow the growth of tumor cells. Although, chemotherapy also affects healthy cells in the body which leads to various side effects.

For instance, the Leukemia Foundation states that chemotherapy can harm fast-growing normal cells, such as hair cells and cells that make up tissues in the mouth, gut, and bone marrow. Additionally, chemotherapy can impact the bone marrow's capability to generate sufficient amounts of blood cells, leading to a decrease in blood count within a week of treatment. Hence, owing to the above factors, the market is expected to hamper over the forecast period.

For more details on this report - Request for Sample

Segment Analysis

The global bone cancer treatment market is segmented based on type, treatment, end users, and region.

Chemotherapy is commonly used for the treatment of various cancers including bone cancers by using anti-cancer drugs to destroy the bone tumor cells. Chemotherapy is expected to hold the largest market share over the period forecast owing to increasing clinical trials conducted for bone cancers with chemotherapy treatment drugs. A total of 446 clinical trials were performed for the treatment of bone cancers with chemotherapy drugs.

For instance, according to clinicalTrials.gov, on July 3, 2023, the School of Medicine, Zhejiang University conducted a clinical trial on the Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in Osteosarcoma. This study aims to explore the tumor necrosis rate in osteosarcoma patients treated with a neoadjuvant regimen of surufatinib combined with chemotherapy.

Additionally, on December 9, 2022, UNICANCER conducted a clinical trial on Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High-Risk Osteosarcoma Patients. The study aims to evaluate the impact on the efficacy of mifamurtide as an add-on treatment to post-operative chemotherapy compared to post-operative chemotherapy alone in first-line treatment of patients with high-risk osteosarcoma.

Geographical Penetration

North America accounted for approximately 38.4% of the market share in 2022

The global bone cancer treatment market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa. North America has maintained a significant proportion of the bone cancer treatment market in recent years, and this trend is anticipated to continue throughout the forecast period due to factors such as the rising incidence of bone cancers, FDA approvals, and research and developments in bone cancer treatment.

For instance, the American Cancer Society's estimation for primary cancer of the bones and joints for 2023 is about 3,970 new cases diagnosed (2,160 in males; 1, 810 in females) and around 2,140 deaths in the United States.

In April 2023, Sumitomo Pharma Oncology, Inc. received an FDA orphan drug designation for TP-1287, an investigational oral CDK9 inhibitor, for the treatment of patients with Ewing sarcoma. TP-1287 exhibits potent inhibition of intracellular kinases including CDK9. Inhibition of CDK9 leads to downregulation of key antiapoptotic proteins such as MCL-1, which in turn has been shown to inhibit tumor growth.

Competitive Landscape

The major global players in the market include: Pfizer Inc., MicroBiopharm Japan Co. Ltd., Sterling Biotech Ltd., Teva Pharmaceuticals Industries Ltd., Cipla Ltd., Aspen API Inc., Eli Lilly and Company, Gatewell Oncology Pvt. Ltd., Recordati Rare Diseases Inc., Novartis AG among others.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the global bone cancer treatment market. During the height of the pandemic, many healthcare systems were overwhelmed, and non-urgent medical procedures and screenings were postponed or canceled. This led to delays in bone cancer treatment research and product launches. Clinical trials are vital for developing new treatments and improving outcomes in the bone cancer treatment market.

However, the pandemic disrupted the conduct of clinical trials, with many sites temporarily halting enrollment or modifying protocols to prioritize patient safety. This has led to delays in the completion of trials and the availability of new therapies. Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. Therefore, owing to the above factors, the bone cancer treatment market is expected to be moderately affected over the forecast period.

By Type

  • Primary Bone Cancer
    • Osteosarcoma
    • Chondrosarcoma
    • Ewing Sarcoma
    • Chordoma
  • Secondary Bone Cancer
    • Bone Metastasis

By Treatment

  • Surgery
  • Chemotherapy
    • Doxorubicin
    • Cisplatin
    • Etoposide
    • Vincristine
  • Radiation Therapy
    • Proton-Beam Radiation Therapy
    • Stereotactic Radiosurgery
    • Intensity-Modulated Radiation Therapy
      • Targeted Therapy
      • Immunotherapy
      • Others

By End Users

  • Hospitals
  • Oncology Centers
  • Ambulatory Surgical Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In July 2023, a Korean drug developer, MedPacto's drug vactosertib received the European Medicines Agency (EMA's) orphan drug designation for the treatment of osteosarcoma.
  • In August 2022, Inhibrx Inc. declared that the European Commission has granted an orphan medicinal product designation to INBRX-109 for use as a potential therapeutic option in patients with chondrosarcoma. The drug is based on a single-domain antibody platform which comprises 2 identical camelid heavy chain-only antibody-binding domains targeting DR5.

Why Purchase the Report?

  • To visualize the global bone cancer treatment market segmentation based on type, treatment, end users, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of global bone cancer treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global bone cancer treatment market report would provide approximately 61 tables, 60 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Treatment
  • 3.3. Snippet by End Users
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Research and Developments for Bone Cancers
      • 4.1.1.2. Rising Investments for Bone Cancer Treatment
    • 4.1.2. Restraints
      • 4.1.2.1. Aftereffects Associated with Chemotherapy
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis
  • 5.5. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Primary Bone Cancer
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Osteosarcoma
    • 7.2.4. Chondrosarcoma
    • 7.2.5. Ewing Sarcoma
    • 7.2.6. Chordoma
  • 7.3. Secondary Bone Cancer
    • 7.3.1. Bone Metastasis

8. By Treatment

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 8.1.2. Market Attractiveness Index, By Treatment
  • 8.2. Surgery
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Chemotherapy
    • 8.3.1. Doxorubicin
    • 8.3.2. Cisplatin
    • 8.3.3. Etoposide
    • 8.3.4. Vincristine
  • 8.4. Radiation Therapy
    • 8.4.1. Proton-Beam Radiation Therapy
    • 8.4.2. Stereotactic Radiosurgery
    • 8.4.3. Intensity-Modulated Radiation Therapy
  • 8.5. Targeted Therapy
  • 8.6. Immunotherapy
  • 8.7. Others

9. By End Users

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 9.1.2. Market Attractiveness Index, By End Users
  • 9.2. Hospitals
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Oncology Centers
  • 9.4. Ambulatory Surgical Centers
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Product Benchmarking
  • 11.3. Company Share Analysis
  • 11.4. Key Developments and Strategies

12. Company Profiles

  • 12.1. Pfizer Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. MicroBiopharm Japan Co. Ltd.
  • 12.3. Sterling Biotech Ltd.
  • 12.4. Teva Pharmaceuticals Industries Ltd.
  • 12.5. Cipla Ltd.
  • 12.6. Aspen API Inc.
  • 12.7. Eli Lilly and Company
  • 12.8. Gatewell Oncology Pvt. Ltd.
  • 12.9. Recordati Rare Diseases Inc.
  • 12.10. Novartis AG

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us